Get started
NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT)NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT)NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT)

NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0UNL chart


Full chart

0UNL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪397.23 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−9.515 USD
Net income (FY)
‪−118.96 M‬ USD
Revenue (FY)
‪98.43 M‬ USD
Shares float
‪16.86 M‬
Beta (1Y)
4.61

Employees


Employees (FY)
61
Change (1Y)
−76 −55.47%
Revenue / Employee (1Y)
‪1.61 M‬ USD
Net income / Employee (1Y)
‪−1.95 M‬ USD

About Nektar Therapeutics


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Howard W. Robin
Website
nektar.com
Headquarters
San Francisco
Founded
1990
FIGI
BBG00LG7G039
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Check out other big names from the same industry as 0UNL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0UNL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0UNL is 22.590 USD — it has increased by 2.61% in the past 24 hours. Watch NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) stocks are traded under the ticker 0UNL.
0UNL stock has fallen by −5.98% compared to the previous week, the month change is a 79.30% rise, over the last year NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) has showed a 12.40% increase.
We've gathered analysts' opinions on NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) future price: according to them, 0UNL price has a max estimate of 120.00 USD and a min estimate of 69.00 USD. Watch 0UNL chart and read a more detailed NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) stock forecast: see what analysts think of NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) and suggest that you do with its stocks.
0UNL reached its all-time high on Sep 5, 2018 with the price of 1,027.350 USD, and its all-time low was 6.525 USD and was reached on Nov 13, 2023. View more price dynamics on 0UNL chart.
See other stocks reaching their highest and lowest prices.
0UNL stock is 8.10% volatile and has beta coefficient of 4.61. Track NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) there?
Today NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) has the market capitalization of ‪397.23 M‬, it has decreased by −3.82% over the last week.
Yes, you can track NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) financials in yearly and quarterly reports right on TradingView.
NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
0UNL earnings for the last quarter are −3.60 USD per share, whereas the estimation was −2.56 USD resulting in a −40.39% surprise. The estimated earnings for the next quarter are −3.03 USD per share. See more details about NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) earnings.
NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) revenue for the last quarter amounts to ‪10.46 M‬ USD, despite the estimated figure of ‪15.35 M‬ USD. In the next quarter, revenue is expected to reach ‪9.49 M‬ USD.
0UNL net income for the last quarter is ‪−50.88 M‬ USD, while the quarter before that showed ‪7.26 M‬ USD of net income which accounts for −800.76% change. Track more NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) financial stats to get the full picture.
No, 0UNL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 3, 2025, the company has 61 employees. See our rating of the largest employees — is NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) EBITDA is ‪−136.62 M‬ USD, and current EBITDA margin is −130.78%. See more stats in NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) financial statements.
Like other stocks, 0UNL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) stock shows the buy signal. See more of NEKTAR THERAPEUTICS USD0.0001 (REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.